You are viewing: India Immunotherapy Drugs Market analysis
Part of: Immunotherapy Drugs Market (Global)

The India Immunotherapy Drugs Market was valued at $5500 Million in 2024 and projected to reach to $11500 Million by 2029, representing a compound annual growth rate of 15.8%. India's immunotherapy drugs market is poised for exceptional growth over the next five years, driven by escalating cancer prevalence, expanding healthcare accessibility, and increased pharmaceutical R&D investments.

India Immunotherapy Drugs Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Immunotherapy Drugs Market Trends and Insights

  • This expansion in India reflects increasing cancer prevalence, rising healthcare investments, and growing adoption of checkpoint inhibitors and CAR-T cell therapies across major metropolitan centers.
  • India's immunotherapy market is being driven by improved patient access, expanding clinical trial infrastructure, and government initiatives to enhance oncology care delivery. The forecast period through 2029 positions India as a critical growth market within the Asia Pacific region for immunotherapy drugs.
  • India's market expansion is supported by a large patient population, cost-effective manufacturing capabilities, and increasing collaboration between domestic and international pharmaceutical companies.
  • By 2029, India is expected to capture significant market share as biosimilar immunotherapies and generic formulations become more widely available, making treatments more accessible to India's diverse healthcare ecosystem..

Key Market Statistics

  • CAGR (2024-2029) 15.8% CAGR
  • Market Size, 2024 ~USD 5500 Million
  • Forecast, 2029 ~USD 11500 Million
  • Country India

India Immunotherapy Drugs Market Overview

Rapid Market Expansion :

India's immunotherapy drugs market is projected to double from USD 5,500 million in 2024 to USD 11,500 million by 2029, driven by increasing cancer incidence and healthcare modernization across the country.

Strong CAGR Performance :

With a CAGR of 15.8%, India's immunotherapy market is outpacing the global average of 15.3%, reflecting accelerated adoption of advanced cancer therapies in emerging metropolitan centers.

Therapy Innovation Adoption :

Checkpoint inhibitors and CAR-T cell therapies are gaining significant traction in India's major cities, supported by improved healthcare infrastructure and increased patient awareness of immunotherapy options.

Healthcare Investment Surge :

Rising government and private sector investments in oncology infrastructure, coupled with growing pharmaceutical manufacturing capabilities, are positioning India as a key immunotherapy hub in Asia.

India Immunotherapy Drugs Market Dynamics

  • The country's growing middle class and improving diagnostic capabilities are enabling earlier disease detection and treatment adoption.
  • Government initiatives promoting affordable healthcare and domestic drug manufacturing are further accelerating market penetration.
  • Major metropolitan areas are witnessing rapid uptake of advanced immunotherapies, while tier-2 and tier-3 cities present untapped growth opportunities.
  • The convergence of rising healthcare spending, supportive regulatory frameworks, and increasing clinical trial activities positions India as a critical growth engine for the global immunotherapy market..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • Merck KGaA
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • India's immunotherapy drugs market is valued at USD 5,500 million in 2024 and is forecast to double to USD 11,500 million by 2029.
    • India is experiencing a 15.8% CAGR, outpacing the global average of 15.3%, driven by rising cancer incidence and healthcare modernization.
    • India's market growth is supported by cost-effective manufacturing, biosimilar development, and expanding clinical trial networks.
    • By 2029, India is positioned to become a major hub for immunotherapy drug accessibility and production within Asia Pacific.

    Immunotherapy Drugs Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment OTHER IMMUNOTHERAPY DRUGS (Type)
    Forecast Period 2024-2029
    Growth Rate CAGR of 15.3% from 2024 to 2029
    Largest Segment HOSPITALS (End User)
    Market Size Base Year (Billions) ~USD 284.92 (2024)
    Revenue Forecast (Billions) ~USD 580.6 (2029)
    Segments Covered Type, Application, Route Of Administration, End User

    India Immunotherapy Drugs Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Type

    • Antibody Drugs
    • Cancer Vaccines
    • Inhibitor Drugs
    • Interferons & Interleukins
    • Other Immunotherapy Drugs

    By Application

    • Autoimmune & Inflammatory Diseases
    • Cancer
    • Hematology
    • Neurology
    • Osteology
    • Other Applications

    By Route Of Administration

    • Intravenous Route Of Administration
    • Other Route Of Administration
    • Other Routes Of Administration
    • Subcutaneous Route Of Administration

    By End User

    • Hospitals
    • Long-Term Care Facilities
    • Other End Users

    Target Audience

    • Pharmaceutical Companies : Pharmaceutical manufacturers and biotech firms need India-specific market data to evaluate market entry strategies, identify partnership opportunities, and optimize product positioning in this high-growth immunotherapy market.
    • Healthcare Investors : Investment firms and venture capitalists require detailed India market analysis to identify lucrative investment opportunities in immunotherapy startups, hospital networks, and diagnostic companies operating in the country.
    • Hospital & Clinic Networks : Healthcare providers and oncology centers need market insights to plan immunotherapy service expansion, procurement strategies, and capacity building aligned with India's growing patient demand.
    • Medical Device Manufacturers : Device companies developing diagnostic and treatment delivery systems require India-specific market intelligence to understand adoption rates, regulatory requirements, and distribution partnerships for immunotherapy applications.
    • Government & Policy Makers : Healthcare policymakers and government agencies need comprehensive market data to design effective healthcare policies, pricing frameworks, and infrastructure investments supporting immunotherapy accessibility across India.

    Reasons to Buy this Report

    • India-Specific Market Sizing : Access precise market valuations and forecasts tailored to India's unique healthcare landscape, enabling accurate investment planning and resource allocation for the Indian immunotherapy sector.
    • Competitive Landscape Intelligence : Understand India's competitive dynamics, including local and international players, market consolidation trends, and emerging competitors in checkpoint inhibitors and CAR-T cell therapy segments.
    • Regulatory & Reimbursement Insights : Gain detailed knowledge of India's drug approval processes, pricing regulations, insurance coverage patterns, and government healthcare schemes affecting immunotherapy market accessibility and profitability.
    • Growth Driver Analysis : Identify key catalysts specific to India including rising cancer incidence, healthcare infrastructure expansion, manufacturing capabilities, and patient demographics driving the 15.8% CAGR.
    • Strategic Market Entry Guidance : Develop informed go-to-market strategies for India with insights on metropolitan adoption patterns, distribution channels, pricing strategies, and partnership opportunities in the immunotherapy ecosystem.

    Frequently asked questions

    What is the current size of India's immunotherapy drugs market?

    India's immunotherapy drugs market was valued at USD 5,500 million in 2024 and is projected to reach USD 11,500 million by 2029.

    What is the expected growth rate for immunotherapy drugs in India?

    India's immunotherapy drugs market is expected to grow at a compound annual growth rate (CAGR) of 15.8% from 2024 to 2029.

    What factors are driving immunotherapy drug adoption in India?

    Key drivers include rising cancer prevalence, government healthcare initiatives, expanding clinical trial infrastructure, cost-effective manufacturing, and increasing availability of biosimilar immunotherapies in India.

    Which immunotherapy drug types are most prevalent in India?

    Checkpoint inhibitors and CAR-T cell therapies are among the most adopted immunotherapy drug types in India, with growing penetration in major metropolitan centers.

    How does India's immunotherapy market compare to global trends?

    India's 15.8% CAGR exceeds the global average of 15.3%, positioning India as a faster-growing market within the Asia Pacific region for immunotherapy drugs.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the current size of the immunotherapy drugs market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the immunotherapy drugs market. The secondary sources referred to for this research study include publications from government sources, such as National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), World Health Organization (WHO), European Pharmaceutical Review, American Society of Gene & Cell Therapy (ASGCT), European Society of Gene and Cell Therapy (ESGCT), European Medicines Agency (EMA), and the Alliance for Regenerative Medicine (ARM). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the immunotherapy drugs market, which was validated through primary research. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess the prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

    Immunotherapy  Drugs Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the immunotherapy drugs market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the immunotherapy drugs and other dependent submarkets. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    Immunotherapy  Drugs Market Size, and Share

    To know about the assumptions considered for the study, Request for Free Sample Report

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes—the market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the immunotherapy drugs market.

    Market Definition

    Immunotherapy drugs are a broad category of therapeutic agents that help stimulate the body's immune system to combat diseases. These drugs include antibody therapies, cell & gene therapy, inhibitor drugs, and other drugs such as oncolytic viral therapy and cancer vaccines. These drugs are engineered to enhance the immune response or counteract the immune system's regulatory mechanisms, thereby enabling the body to effectively target and eliminate disease-causing agents or cells. Immunotherapy drugs are used to treat various medical conditions, including cancer, autoimmune diseases, hematology, osteology, neurology, and other therapy areas (such as ophthalmology, dermatology, and cardiovascular disorders).

    Stakeholders

    • Research Institutes
    • Pharmaceutical & Biotechnology Companies
    • Venture Capitalists and Investors
    • Contract Development & Manufacturing Organizations
    • Government Associations
    • Healthcare Associations/Institutes
    • Business Research & Consulting Service Providers

    Report Objectives

    • To define, describe, and forecast the immunotherapy market based on type,  application, route of administrration, end user, and region
    • To provide detailed information about the drivers, restraints, opportunities, and challenges influencing the market growth
    • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall immunotherapy drugs market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of market segments in North America, Europe, the Asia Pacific (APAC), Latin America, Middle East and Africa
    • To profile the key players and comprehensively analyze their core competencies2 in terms of key developments, product portfolios, and financials
    • To track and analyze competitive developments, such as partnerships, collaborations, agreements, and acquisitions, in the immunotherapy drugs market
    • Micromarkets are the further segments and subsegments of the immunotherapy drugs market.
    • Core competencies of companies are captured in terms of the key developments, market shares, and key strategies adopted to sustain their positions in the market.

    Available Customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    • Company Information: Detailed analysis and profiling of additional market players (up to five)
    • Geographic Analysis: Further breakdown of the Rest of Europe market, by country, based on approvals and feasibility. Further breakdown of the Rest of Asia Pacific market, by country, based on approvals and feasibility

    Get the Full Immunotherapy Drugs Market Report

    Full forecast, segment splits, and company analysis for all Immunotherapy Drugs Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status